New Insights into the Management of Hyperparathyroidism in Dialysis and Kidney Transplant Patients

About the Symposium
Mineral and bone disorders (MBD) are common complications in patients with chronic kidney disease (CKD) who undergo maintenance dialysis treatment and may persist even after successful kidney transplantation. CKD-MBD includes bone disorders, secondary hyperparathyroidism (sHPT), mineral disarrays, and vascular calcification. Recent evidence suggests that CKD-MBD, and in particular sHPT, is associated with significant morbidity and mortality in dialysis and transplant patients.

This symposium reviews new insights into our understanding of the pathophysiology and management of sHPT in the dialysis and kidney transplant populations. The first lecture discusses and compares traditional and novel markers in the diagnosis and management of sHPT and refractory hyperparathyroidism in dialysis and transplant patients, including parathyroid hormone, alkaline phosphatase, minerals, fibroblast growth factor-23, imaging studies, and bone biopsies. Next, the challenge of therapy with vitamin D sterol compounds with regard to hypercalcemia and hyperphosphatemia is reviewed and compared with combination therapy of sHPT, including the balanced use of vitamin D analogs, nutritional (native) vitamin D, calcimimetics, and phosphorus binders for improving outcomes in maintenance dialysis patients. The final lecture focuses on persistent hyperparathyroidism after kidney transplantation and the role of traditional interventions such as parathyroidectomy and newer agents, including calcimimetics, in the management of transplant patients.

Accreditation Statement
The American Society of Nephrology (ASN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement
ASN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Original Release and Last Review Date
January 2013

CME Credit and Post-Test Termination Date
December 31, 2013

Estimated Time to Complete Program
One (1) hour.

Who Should Participate
- Physicians
- Researchers
- Physicians-in-training — including medical students, residents, and fellows — and other trainees
- Nurses and nurse practitioners
- Pharmacists
- Physician assistants
- Other health care professionals

Learning Objectives
Upon completion of this symposium, the participant will be able to: 1) discuss the role of traditional and novel markers in the diagnosis and management of secondary and refractory hyperparathyroidism and compare the utility of these markers in chronic dialysis and kidney transplant patients; 2) examine past and current data on the association of vitamin D sterol therapy with hypercalcemia and hyperphosphatemia in dialysis and transplant patients; 3) appraise the role of different therapeutic agents and their combinations in the treatment of secondary hyperparathyroidism in dialysis patients; and 4) compare recent data on the management of posttransplant hyperparathyroidism using both traditional approaches and calcimimetics.

Disclosure Statement
It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN’s sponsored Continuing Education (CE) activities are expected to provide full disclosure for both themselves and their spouse/partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 12 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their
presentation. Participants should note that the use of products outside U.S. Food and Drug Administration (FDA) approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

View the full ASN Conflict of Interest and Disclosure Policy.

Faculty, Planner, and Staff Disclosure

Steven M. Brunelli, MD  
DaVita Clinical Research  
Rochester, NY  
Current Employer: DaVita Clinical Research. Wife employed by AstraZeneca.

Kamyar Kalantar-Zadeh, MD, PhD, FASN  
University of California, Irvine School of Medicine  
Orange, CA  
Consultancy Agreements: Abbott, Amgen, DaVita, Fresenius, Otsuka, Shire, Vifor  
Research Funding: Abbott, DaVita, Shire, NIH, NKF  
Honoraria: Abbott, Amgen, DaVita, Fresenius, Otsuka, Shire, Vifor  
Scientific Advisor or Membership: NIH (several study sections), NKF (SAB), Abbott, Amgen, DaVita, Fresenius, Otsuka, Shire, Vifor, AJKD, JRTEN, ACKD, J Cachexia Sarcopenia Muscle, IUN, RUN

Mary B. Leonard, MD  
Children's Hospital of Philadelphia  
Philadelphia, PA  
Consultancy Agreements: Amgen, Inc., Johnson & Johnson  
Scientific Advisor or Membership: Marodyne Medical Scientific Advisory Board

Stuart M. Sprague, DO, FASN  
North Shore Univ Health System  
Evanston, IL  
Consultancy Agreements: Cytochroma, Vifor Pharma, Kai Pharmaceuticals, Litholink Corp.  
Research Funding: Abbott, Amgen, Shire, Cytochroma, Vifor Pharma, Reata  
Scientific Advisor or Membership: NKF of Illinois, American Journal of Nephrology, CJASN, ASN Conflict of Interest Management Committee, International Federation of Clinical Chemistry and Laboratory Medicine-Work Group for Parathyroid Hormone  
Other Interests: Rockwell Medical CRUISE Study (Data Safety Monitoring Board)

ASN staff have nothing to disclose.

Hardware/Software Requirements

Computers  
Any computer running Windows and Mac OS machines are supported.

System Requirements  
For a successful viewing experience, the following hardware and software are required:  
Broadband cable, DSL or high-speed Internet connection  
IE9, Firefox 8, Chrome 10 or higher for streaming  
533 MHz or faster processor  
At least 512 MB RAM  
Adobe Reader 9 or latest (free download at www.adobe.com)  
Adobe Flash Player v. 9 or higher (free download at www.adobe.com)  
Please be sure you are able to play mp3’s on your computer.

Method of Participation  
Listen and view the streaming media with slides.  
Complete the program evaluation.  
Complete the post-test questions.
Medium or Combination of Media Used
Streaming media of slides with audio

Educational Symposium at Kidney Week 2012 Live Activity Participants
You will not receive credit for completing this activity if you previously completed and received credit for the live CME activity.

Educational Symposium Support
This activity is supported by an educational donation provided by Amgen.

Privacy Policy/Confidentiality
As a condition of your access and use of the Website, you agree not to use the Website for any purpose that is unlawful or inconsistent with the Agreement. ASN, in its sole discretion, is authorized to remove or delete any entries, information, materials, or other content that violates these Terms of Use or that is otherwise objectionable. ASN reserves the right to investigate and prosecute violations of any of these Terms of Use to the fullest extent of the law. If Users fail to comply with these Terms of Use, ASN in its sole discretion may terminate the User's access to the website immediately without advance notice. These terms of use comprise an Agreement that is governed by the laws of the District of Columbia, which shall be the forum for any disputes.

Disclaimer
The American Society of Nephrology ("ASN") does not offer medical advice. All content in ASN publications, including this website, is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Contact Information
For any questions concerning this activity, please contact ASN at 202-640-4660 or education@asn-online.org.